Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Chen CH
------>authors3_c=None
------>paper_class1=2
------>Impact_Factor=None
------>paper_class3=0
------>paper_class2=0
------>vol=
------>confirm_bywho=None
------>insert_bywho=chshih43
------>Jurnal_Rank=None
------>authors4_c=None
------>comm_author=
------>patent_EDate=None
------>authors5_c=None
------>publish_day=None
------>paper_class2Letter=None
------>page2=
------>medlineContent=
------>unit=000
------>insert_date=20041030
------>iam=2
------>update_date=None
------>author=???
------>change_event=1
------>ISSN=None
------>authors_c=None
------>score=136
------>journal_name=The 1985 Congress of Thoracic
------>paper_name=The diagnostic value of serum CEA and TPA in lung cancer.
------>confirm_date=None
------>tch_id=093156
------>pmid=11844959
------>page1=10
------>fullAbstract=BACKGROUND: The role of tumor markers in the diagnosis and prognosis of lung cancer is under investigation. OBJECTIVES: The aim of this study was to investigate the diagnostic and prognostic significance of pre-therapeutic levels of various serum tumor markers, CYFRA 21-1, neuron-specific enolase (NSE), tissue polypeptide antigen (TPA), carcinoembryonic antigen (CEA), CA 125 and squamous cell carcinoma antigen (SCCAg), in patients with lung cancer. METHODS: We studied 102 consecutive patients (mean age 65.2 +/- 11 years) with newly diagnosed lung cancer (96 males, 94%, with a mean age of 66.3 +/-10.5 years). All patients had a 5-year follow-up. Measurements of the serum tumor markers were performed on initial diagnosis. RESULTS: Eighty-four patients (82%) had non-small-cell lung cancer (NSCLC) and 18 (18%) small-cell lung cancer (SCLC). From the 84 patients with NSCLC, 34 patients (33%) had squamous-cell lung cancer, 23 (22%) adenocarcinoma and 23 (22%) large-cell carcinomas. The overall median survival was 8.5 months. All SCLC patients had extensive disease with a median survival of 10.1 months and NSCLC patients of 8.4 months. Significant differences in the mean values of NSE and CYFRA 21-1 were observed between SCLC and NSCLC. In NSCLC, CYFRA 21-1, TPA, CA 125 and SCCAg serum levels were related to the stage of the disease at diagnosis, and CYFRA 21-1, NSE, TPA and CA-125 were related to a poor outcome. None of the above tumor markers was related to survival in the SCLC group. CONCLUSION: CYFRA 21-1 and NSE may help to differentiate cell types in lung cancer patients. Also, CYFRA 21-1 with TPA and CA 125 may provide useful information regarding the staging of the disease at diagnosis and the prognosis of patients with NSCLC.
------>tmu_sno=None
------>sno=10213
------>authors2=Shue CH
------>authors3=Yen TC
------>authors4=Lu JY
------>authors5=Perng RP
------>authors6=
------>authors6_c=None
------>authors=Chen CH
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=None
------>publish_area=None
------>updateTitle=Prognostic value of serum tumor markers in patients with lung cancer.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=1985
------>submit_flag=None
------>publish_month=None
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z